Publication

GDF-15 (Growth Differentiation Factor 15) Is Associated With Hospitalization and Mortality in Patients With a Fontan Circulation

Meyer, S. L., Wolff, D., Ridderbos, F-J. S., Eshuis, G., Hillege, H., Willems, T. P., Ebels, T., van Melle, J. P. & Berger, R. M. F., 8-May-2020, In : Journal of the American Heart Association. 9, 10, e015521.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Meyer, S. L., Wolff, D., Ridderbos, F-J. S., Eshuis, G., Hillege, H., Willems, T. P., ... Berger, R. M. F. (2020). GDF-15 (Growth Differentiation Factor 15) Is Associated With Hospitalization and Mortality in Patients With a Fontan Circulation. Journal of the American Heart Association, 9(10), [e015521]. https://doi.org/10.1161/JAHA.119.015521

Author

Meyer, Sophie L ; Wolff, Djoeke ; Ridderbos, Floris-Jan S ; Eshuis, Graziella ; Hillege, Hans ; Willems, Tineke P ; Ebels, Tjark ; van Melle, Joost P ; Berger, Rolf M F. / GDF-15 (Growth Differentiation Factor 15) Is Associated With Hospitalization and Mortality in Patients With a Fontan Circulation. In: Journal of the American Heart Association. 2020 ; Vol. 9, No. 10.

Harvard

Meyer, SL, Wolff, D, Ridderbos, F-JS, Eshuis, G, Hillege, H, Willems, TP, Ebels, T, van Melle, JP & Berger, RMF 2020, 'GDF-15 (Growth Differentiation Factor 15) Is Associated With Hospitalization and Mortality in Patients With a Fontan Circulation', Journal of the American Heart Association, vol. 9, no. 10, e015521. https://doi.org/10.1161/JAHA.119.015521

Standard

GDF-15 (Growth Differentiation Factor 15) Is Associated With Hospitalization and Mortality in Patients With a Fontan Circulation. / Meyer, Sophie L; Wolff, Djoeke; Ridderbos, Floris-Jan S; Eshuis, Graziella; Hillege, Hans; Willems, Tineke P; Ebels, Tjark; van Melle, Joost P; Berger, Rolf M F.

In: Journal of the American Heart Association, Vol. 9, No. 10, e015521, 08.05.2020.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Meyer SL, Wolff D, Ridderbos F-JS, Eshuis G, Hillege H, Willems TP et al. GDF-15 (Growth Differentiation Factor 15) Is Associated With Hospitalization and Mortality in Patients With a Fontan Circulation. Journal of the American Heart Association. 2020 May 8;9(10). e015521. https://doi.org/10.1161/JAHA.119.015521


BibTeX

@article{acc28ff714b14d0cbbd94994f834667f,
title = "GDF-15 (Growth Differentiation Factor 15) Is Associated With Hospitalization and Mortality in Patients With a Fontan Circulation",
abstract = "Background We investigated serial serum levels of GDF-15 (growth differentiation factor 15) in Fontan patients and their relation to outcome. Methods and Results In this single-center prospective study of consecutive Fontan patients, serial serum GDF-15 measurement and clinical assessment was done at baseline (n=81) and after 2 years (n=51). The association between GDF-15 and the combined end point of all-cause mortality, heart transplant listing, and Fontan-related hospitalization was investigated. Median age at baseline was 21 years (interquartile range: 15-28 years). Median GDF-15 serum levels at baseline were 552 pg/mL (interquartile range: 453-729 pg/mL). GDF-15 serum levels correlated positively with age, age at Fontan initiation, New York Heart Association class, and serum levels of NT-proBNP (N-terminal pro-B-type natriuretic peptide) and ɣGT (γ-glutamyltransferase) and negatively with exercise capacity. During a median follow-up of 4.8 years (interquartile range: 3.3-5.5 years), the combined end point occurred in 30 patients (37{\%}). Multivariate Cox regression showed that patients with the highest baseline GDF-15 (n=20, defined as the upper quartile) had a higher risk of hospitalization or death than the lowest 3 quartiles (hazard ratio [HR], 2.76; 95{\%} CI, 1.27-6.00; P=0.011). After 2 years of follow-up, patients in whom serum level of GDF-15 increased to >70 pg/mL (n=13) had a higher risk of hospitalization or death than the lowest 3 quartiles (HR, 2.69; 95{\%} CI, 1.03-6.99; P=0.043). Conclusions In Fontan patients, elevated serum levels of GDF-15 are associated with worse functional status and predict Fontan-related events. Furthermore, serial measurements showed that an increase in GDF-15 serum level was associated with increased risk for adverse outcome.",
author = "Meyer, {Sophie L} and Djoeke Wolff and Ridderbos, {Floris-Jan S} and Graziella Eshuis and Hans Hillege and Willems, {Tineke P} and Tjark Ebels and {van Melle}, {Joost P} and Berger, {Rolf M F}",
year = "2020",
month = "5",
day = "8",
doi = "10.1161/JAHA.119.015521",
language = "English",
volume = "9",
journal = "Journal of the American Heart Association",
issn = "2047-9980",
publisher = "Wiley",
number = "10",

}

RIS

TY - JOUR

T1 - GDF-15 (Growth Differentiation Factor 15) Is Associated With Hospitalization and Mortality in Patients With a Fontan Circulation

AU - Meyer, Sophie L

AU - Wolff, Djoeke

AU - Ridderbos, Floris-Jan S

AU - Eshuis, Graziella

AU - Hillege, Hans

AU - Willems, Tineke P

AU - Ebels, Tjark

AU - van Melle, Joost P

AU - Berger, Rolf M F

PY - 2020/5/8

Y1 - 2020/5/8

N2 - Background We investigated serial serum levels of GDF-15 (growth differentiation factor 15) in Fontan patients and their relation to outcome. Methods and Results In this single-center prospective study of consecutive Fontan patients, serial serum GDF-15 measurement and clinical assessment was done at baseline (n=81) and after 2 years (n=51). The association between GDF-15 and the combined end point of all-cause mortality, heart transplant listing, and Fontan-related hospitalization was investigated. Median age at baseline was 21 years (interquartile range: 15-28 years). Median GDF-15 serum levels at baseline were 552 pg/mL (interquartile range: 453-729 pg/mL). GDF-15 serum levels correlated positively with age, age at Fontan initiation, New York Heart Association class, and serum levels of NT-proBNP (N-terminal pro-B-type natriuretic peptide) and ɣGT (γ-glutamyltransferase) and negatively with exercise capacity. During a median follow-up of 4.8 years (interquartile range: 3.3-5.5 years), the combined end point occurred in 30 patients (37%). Multivariate Cox regression showed that patients with the highest baseline GDF-15 (n=20, defined as the upper quartile) had a higher risk of hospitalization or death than the lowest 3 quartiles (hazard ratio [HR], 2.76; 95% CI, 1.27-6.00; P=0.011). After 2 years of follow-up, patients in whom serum level of GDF-15 increased to >70 pg/mL (n=13) had a higher risk of hospitalization or death than the lowest 3 quartiles (HR, 2.69; 95% CI, 1.03-6.99; P=0.043). Conclusions In Fontan patients, elevated serum levels of GDF-15 are associated with worse functional status and predict Fontan-related events. Furthermore, serial measurements showed that an increase in GDF-15 serum level was associated with increased risk for adverse outcome.

AB - Background We investigated serial serum levels of GDF-15 (growth differentiation factor 15) in Fontan patients and their relation to outcome. Methods and Results In this single-center prospective study of consecutive Fontan patients, serial serum GDF-15 measurement and clinical assessment was done at baseline (n=81) and after 2 years (n=51). The association between GDF-15 and the combined end point of all-cause mortality, heart transplant listing, and Fontan-related hospitalization was investigated. Median age at baseline was 21 years (interquartile range: 15-28 years). Median GDF-15 serum levels at baseline were 552 pg/mL (interquartile range: 453-729 pg/mL). GDF-15 serum levels correlated positively with age, age at Fontan initiation, New York Heart Association class, and serum levels of NT-proBNP (N-terminal pro-B-type natriuretic peptide) and ɣGT (γ-glutamyltransferase) and negatively with exercise capacity. During a median follow-up of 4.8 years (interquartile range: 3.3-5.5 years), the combined end point occurred in 30 patients (37%). Multivariate Cox regression showed that patients with the highest baseline GDF-15 (n=20, defined as the upper quartile) had a higher risk of hospitalization or death than the lowest 3 quartiles (hazard ratio [HR], 2.76; 95% CI, 1.27-6.00; P=0.011). After 2 years of follow-up, patients in whom serum level of GDF-15 increased to >70 pg/mL (n=13) had a higher risk of hospitalization or death than the lowest 3 quartiles (HR, 2.69; 95% CI, 1.03-6.99; P=0.043). Conclusions In Fontan patients, elevated serum levels of GDF-15 are associated with worse functional status and predict Fontan-related events. Furthermore, serial measurements showed that an increase in GDF-15 serum level was associated with increased risk for adverse outcome.

U2 - 10.1161/JAHA.119.015521

DO - 10.1161/JAHA.119.015521

M3 - Article

VL - 9

JO - Journal of the American Heart Association

JF - Journal of the American Heart Association

SN - 2047-9980

IS - 10

M1 - e015521

ER -

ID: 125487267